

AMENDMENTS TO THE CLAIMS

1-102. (Canceled).

103. (Currently amended) ~~The compound of claim 93, wherein said A compound~~
is selected from the group consisting of ~~Ac-hydroxyacetyl-Asn-Tyr-NH₂, Ac-~~
~~hydroxyacetyl-Asn-Tyr-OH, hydroxyacetyl-Asn-Tyr-NH₂, hydroxyacetyl-Asn-Tyr-OH,~~
~~hydroxyacetyl-Gly-Tyr-NH₂, hydroxyacetyl-Gly-Tyr-OH, acetyl-Asn-Tyr-NH₂, acetyl-~~
~~Asn-Tyr-OH, acetyl-Gly-Tyr-NH₂, and acetyl-Gly-Tyr-OH-Ac-hydroxyacetyl-Gly-Tyr-~~
~~NH₂, and Ac-hydroxyacetyl-Gly-Tyr-OH;~~ or a pharmaceutically acceptable salt thereof.

104. (Canceled)

105. (Currently amended) A pharmaceutical composition comprising:

- (a) a compound of claim 93 103 or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

106-107. (Canceled)

108. (Previously presented) The pharmaceutical composition of claim 105,
wherein said composition is in a form suitable for oral or parenteral administration.

109. (Previously presented) The pharmaceutical composition of claim 108, wherein said form suitable for oral administration is an enteric tablet.

110. (New) Hydroxyacetyl-Asn-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

111. (New) A pharmaceutical composition comprising:

- (a) the compound of claim 110, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

112. (New) The pharmaceutical composition of claim 111, wherein said composition is in a form suitable for oral or parenteral administration.

113. (New) The pharmaceutical composition of claim 112, wherein said form suitable for oral administration is an enteric tablet.

114. (New) Hydroxyacetyl-Asn-Tyr-OH, or a pharmaceutically acceptable salt thereof.

115. (New) A pharmaceutical composition comprising:

- (a) the compound of claim 114, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

116. (New) The pharmaceutical composition of claim 115, wherein said composition is in a form suitable for oral or parenteral administration.

117. (New) The pharmaceutical composition of claim 116, wherein said form suitable for oral administration is an enteric tablet.

118. (New) Hydroxyacetyl-Gly-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

119. (New) A pharmaceutical composition comprising:

- (a) the compound of claim 118, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

120. (New) The pharmaceutical composition of claim 119, wherein said composition is in a form suitable for oral or parenteral administration.

121. (New) The pharmaceutical composition of claim 120, wherein said form suitable for oral administration is an enteric tablet.

122. (New) Hydroxyacetyl-Gly-Tyr-OH, or a pharmaceutically acceptable salt thereof.

123. (New) A pharmaceutical composition comprising:

- (a) the compound of claim 122, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

124. (New) The pharmaceutical composition of claim 123, wherein said composition is in a form suitable for oral or parenteral administration.

125. (New) The pharmaceutical composition of claim 124, wherein said form suitable for oral administration is an enteric tablet.

126. (New) Acetyl-Asn-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

127. (New) A pharmaceutical composition comprising:

- (a) the compound of claim 126, or a pharmaceutically acceptable salt thereof; and

(b) a pharmaceutically acceptable carrier or diluent.

128. (New) The pharmaceutical composition of claim 127, wherein said composition is in a form suitable for oral or parenteral administration.

129. (New) The pharmaceutical composition of claim 128, wherein said form suitable for oral administration is an enteric tablet.

130. (New) Acetyl-Asn-Tyr-OH, or a pharmaceutically acceptable salt thereof.

131. (New) A pharmaceutical composition comprising:

- (a) the compound of claim 130, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

132. (New) The pharmaceutical composition of claim 131, wherein said composition is in a form suitable for oral or parenteral administration.

133. (New) The pharmaceutical composition of claim 132, wherein said form suitable for oral administration is an enteric tablet.

134. (New) Acetyl-Gly-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

135. (New) A pharmaceutical composition comprising:

- (a) the compound of claim 134, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

136. (New) The pharmaceutical composition of claim 135, wherein said composition is in a form suitable for oral or parenteral administration.

137. (New) The pharmaceutical composition of claim 136, wherein said form suitable for oral administration is an enteric tablet.

138. (New) Acetyl-Gly-Tyr-OH, or a pharmaceutically acceptable salt thereof.

139. (New) A pharmaceutical composition comprising:

- (a) the compound of claim 138, or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

140. (New) The pharmaceutical composition of claim 139, wherein said composition is in a form suitable for oral or parenteral administration.

141. (New) The pharmaceutical composition of claim 140, wherein said form suitable for oral administration is an enteric tablet.